2Spannheimer A,Goertz A,Derckmann-Behrendt B.Comparison of therapies with torasemide in patients with congestive heart failure front a pharmacoeconnmic viewpoint[J].Int.J.Clin,Pract.,1998,52(7):467-471.
3Argenziano L,Morisco C,Trimarco B et al.Efficacy and safety of torsemide in patients with moderate congestive beart failure.[J].Curr,Ther Res.1998,59(10):697-709.
4Kondo N,Kimura M,Yamamoto M,et al.Chemical structure and physico-chemical properties of torasenide[J].Iyakuhin Kenkyu,1994,25(9):734-750(CA,122:105616w).
5Delarge J.Chemistry and pharmacological properties of pynidine-3-sulfonylurea derivative torasemide[J].Arzbeun,-Firsch,1988,38(1A):144-150.
6Pascal de T,bernard P,Leon D.Synthesis and structural studies of a new class of heterocylic compounds:1,2,4-pyridothiadiazine 1,1-dioxides,pyridyl analogues of 1,2,4-benzothiadiazine,1,1-dioxides[J].Tetrahedron,1995,51(11):3221-3234.
7Russellf E,Herbert C.The sulfonic acid derived from pyridine and ,2,6-lutidineand the corresponding N-oxides [J].J.Org.Chem.1962,27(4):1329-1336.
